Organigram Global Inc.
OGI • Drug Manufacturers - Specialty & Generic
$1.16
▼ -0.01 (-1.28%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$151.96M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.03Healthy liquidity · 2.26Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 12, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:51 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.16
Change-1.28%
Shares Out131.57M
Market Cap$151.96M
52W Range0.85 - 2.24
Beta1.85
P/E-59.62
P/S3.67
P/B0.59
P/FCF-33.58
EV/Sales3.34
EV/EBITDA-41.90
Price$1.16
Change-1.28%
Shares Out131.57M
Market Cap$151.96M
52W Range0.85 - 2.24
Beta1.85
P/E-59.62
P/S3.67
P/B0.59
P/FCF-33.58
EV/Sales3.34
EV/EBITDA-41.90
EV/FCF-30.49
Earnings Yield-0.42%
FCF Yield-2.98%
Dividend Yield0.00%
Gross Margin3.67%
Oper. Margin-34.07%
Profit Margin-9.55%
Debt/Eq0.03
Current Ratio2.26
Quick Ratio1.28
Volume2.36M
Avg Volume596.91K
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
50
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
62/100
Price Attractiveness
Cheap or expensive today
91/100
Why this score▼
Manageable debt level · 0.03Healthy liquidity · 2.26Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 5 analyst votes · 2026-09-05
60/100
Neutral
Bullish
2
Hold
2
Bearish
1
🧾
No insider activity
No recent insider transactions available.